Representing generic pharmaceutical manufacturer in nationwide antitrust class action brought by direct and indirect drug purchasers challenging a so-called “reverse payment” settlement of Hatch-Waxman patent litigation.
Representing generic pharmaceutical manufacturer in complex multidistrict litigation brought by direct, indirect, and end-payer purchasers alleging “price-fixing” with respect to various pharmaceuticals.
Representing international hotel chain in lawsuit seeking to enforce foreign arbitration award issued against former subsidiary pursuant to alter ego and agency theories of liability.
Representing financial advisory and asset management firm in connection with advice and fairness opinions rendered in various M&A.
Represented a pharmaceutical corporation and its directors and officers in three derivative actions in New York state court arising out of an SEC settlement regarding alleged Foreign Corrupt Practices Act violations, winning motions to dismiss in all three.